The biotech industry is entering 2026 with growing optimism, highlighted by recent improvements in market sentiment and increased activity at industry meetings such as the Jeffries conference in London. This positive trend is also seen in a series of new partnerships, strategic acquisitions, and collaborations with Chinese companies that are influencing investor perspectives.
In a recent discussion hosted by Jennifer Smith-Parker, Director of Insights at BioSpace, industry leaders shared their views on these developments. The guests included Kenneth Galbraith, CEO of Zymeworks, and Josh Smiley, President and Chief Operating Officer of Zai Lab.
"The views expressed in this discussion by guests are their own and do not represent those of their organizations," according to the event disclaimer.
The conversation took place ahead of the J.P. Morgan Healthcare Conference, which is expected to further shape dialogue within the sector. The focus remains on how innovation and international cooperation are contributing to changes in the global biotech landscape.
